Kanavit

Phytomenadione, the active ingredient in Kanavit, is a Vitamin K presented as an injectable solution for intramuscular and intravenous use. It restores normal coagulation by supplying vitamin K1, and is employed to prevent and treat vitamin K deficiency bleeding as well as to reverse anticoagulant therapy such as warfarin in cases of over‑anticoagulation or acute bleeding.

GNH USA supplies Kanavit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing regulatory‑approved product handling, quality assurance and reliable distribution to meet the needs of healthcare providers across global markets.

Kanavit is used to address disorders of the coagulation cascade that involve vitamin K‑dependent clotting factors. - Vitamin K deficiency bleeding: restores clotting factor activity to stop or prevent bleeding. - Warfarin over‑anticoagulation: rapidly reverses anticoagulant effect to normalize coagulation. - Surgical patients on vitamin K antagonists: provides rapid correction of coagulation to allow safe surgery. - Neonatal hemorrhagic disease: supplies vitamin K to prevent bleeding in newborns.

Adverse reactions to Kanavit may vary in frequency and severity.

Common Side Effects: - Injection site pain: mild discomfort at the site of administration. - Redness or swelling: localized erythema and edema at the injection site. - Headache: transient mild to moderate head pain. - Nausea: occasional feeling of queasiness after dosing. - Fever: low‑grade temperature rise within 24 hours. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical intervention. - Severe hypotension: marked drop in blood pressure following injection. - Thrombosis: formation of abnormal clots in veins or arteries. - Hemolysis: destruction of red blood cells, potentially leading to anemia. - Serum sickness: immune‑mediated reaction presenting with rash, fever and arthralgia.

Before using Kanavit, clinicians should consider several safety measures. - Assess vitamin K status: evaluate baseline coagulation before use. - Monitor coagulation parameters: check INR or PT after administration. - Avoid in known hypersensitivity: do not give to patients with documented allergy to vitamin K. - Use cautiously in thrombosis risk: consider patient history of clotting disorders. - Do not mix with incompatible solutions: ensure proper diluent and administration technique. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kanavit may interact with other agents that affect coagulation or vitamin K metabolism.

Major Interactions (Avoid): - Warfarin: concurrent use may diminish anticoagulant effect and require dose adjustment. - Other vitamin K products: combined use can cause excess vitamin K leading to hypercoagulability.

Moderate Interactions (Monitor Closely): - Heparin: additive anticoagulant effect may increase bleeding risk. - Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for altered bleeding profile. - Broad‑spectrum antibiotics: may affect gut flora and vitamin K levels, requiring observation.